TGR BioSciences Pty Ltd (TGR) is located in Adelaide, South Australia. Established in 2001, TGR is committed to providing innovative solutions for cell-based research applications. TGR has R&D, Manufacturing, Quality and Logistics functions and active in the Life Science, Pharmaceutical and Diagnostics markets. In January 2020, TGR was acquired by Abcam whose headquarters are in Cambridge, UK. Abcam develops and produces high-quality biological reagents – primarily RabMabs – which are essential in a wide range of fields and applications including drug discovery, diagnostics and basic research.
TGR’s core products are underpinned by its patented CaptSure™ technology which is characterized by its innovative peptide-antibody immobilization system. The key attributes of TGR’s CaptSure™ technology are simplicity, speed and efficiency and it is these 3 attributes that make CaptSure™ s the ‘go-to’ platform for the development and manufacture of high-quality immunoassays. TGR’s flagship immunoassay range, SureFire® Ultra, underpins a range of assay kits for analysis of cellular phosphoproteins and are manufactured at its facility in Adelaide. SureFire® Ultra kits are distributed exclusively through Revvity, Inc. (USA), a global market leader in laboratory reagents. With over 300 assays on the market TGR’s SureFire® Ultra and SureFire® Multiplex assays provide an unparalleled toolbox for measuring endogenous signaling proteins in a homogeneous format.
All TGR SureFire® Ultra related products are available globally through our exclusive distributor Revvity, visit www.revvity.com. The CaptSure™ SimpleStep ELISA technology is available globally through our parent company, Abcam plc, visit www.abcam.com.